P. Thuss-Patience

Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial

T. Zhan, E. Goekkurt, J. Riera-Knorrenschild, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial

J. Trojan, G. Folprecht, M. Schuler, 2017, Zeitschrift für Gastroenterologie.

Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial

J. Gaedcke, Peter Jo, N. Moosmann, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study.

J. Ajani, F. El hajbi, M. Alsina, 2023, ESMO open.

Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract

R. Hofheinz, M. Moehler, F. Lordick, 2023, Journal of Cancer Research and Clinical Oncology.

Contents of Next Issues · Themenvorschau

J. Drevs, D. Strumberg, U. Massing, 2002, Oncology Research and Treatment.

Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy

E. Goekkurt, T. Dechow, C. Pauligk, 2024, International journal of cancer.

Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study.

T. Zhan, J. Betge, M. Maenz, 2024, Journal of geriatric oncology.